| Literature DB >> 31858764 |
Young Eun Kwon1, Dong Jin Oh1, Moon Jung Kim2, Hye Min Choi3.
Abstract
BACKGROUND: Pyuria seems to be common in chronic kidney disease (CKD), irrespective of urinary tract infection (UTI). It has been hypothesized that sterile pyuria occurs in CKD because of chronic renal parenchymal inflammation. However, there are limited data on whether CKD increases the rate of pyuria or how pyuria in CKD should be interpreted. We investigated the prevalence and characteristics of asymptomatic pyuria (ASP) in CKD via urinary white blood cell (WBC) analysis.Entities:
Keywords: Asymptomatic pyuria; Cellular analysis; Chronic kidney disease; Neutrophil; Prevalence; Sterile
Mesh:
Substances:
Year: 2020 PMID: 31858764 PMCID: PMC6933061 DOI: 10.3343/alm.2020.40.3.238
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Fig. 1The prevalence of pyuria according to the level of renal function. The prevalence of pyuria was investigated in asymptomatic CKD population. CKD was divided into HD and non-dialysis CKD; non-dialysis CKD was further classified as stages 3, 4, and 5 according to the KDIGO classification [11]. The prevalence of pyuria in the non-CKD population was estimated from regular health examination data at the study hospital and included control patients aged >40 years with eGFR ≥60 mL/min/1.73 m2.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HD, hemodialysis; KDIGO, Kidney Disease Improving Global Outcomes.
Baseline and clinical characteristics of the patients with pyuria
| Non-Pyuria (N = 207) | Pyuria (N = 91) | ||
|---|---|---|---|
| Male sex, N (%) | 146 (70.5) | 33 (36.3) | < 0.001 |
| Age (yr) | 70 (57–77) | 71 (59–77) | 0.801 |
| Cause of CKD, N (%) | 0.025 | ||
| Diabetes | 87 (46.8) | 54 (65.9) | |
| Hypertension | 48 (25.8) | 11 (13.4) | |
| Glomerulopathy | 23 (12.4) | 6 (7.3) | |
| Others | 28 (15.1) | 11 (13.4) | |
| Comorbid diabetes, N (%) | 100 (48.3%) | 59 (64.8%) | 0.011 |
| CKD stage*, N (%) | < 0.001 | ||
| Stage 3 | 115 (55.6) | 26 (28.6) | |
| Stages 4 and 5 | 58 (28.0) | 29 (31.9) | |
| HD | 34 (16.4) | 36 (39.6) | |
| Presence of hematuria, N (%) | 32 (15.5) | 29 (31.9) | 0.002 |
| Presence of proteinuria, N (%) | 92 (44.7) | 59 (64.8) | 0.002 |
| Laboratory findings (blood) | |||
| Hb (g/L) | 118.1 ± 20.2 | 109.4 ± 16.2 | < 0.001 |
| WBC (× 109/L) | 6.8 ± 1.9 | 6.8 ± 1.9 | 0.821 |
| hsCRP (nmol/L) | 18.1 ± 22.8 | 33.3 ± 52.4 | 0.012 |
| Alb (g/L) | 40.1 ± 3.2 | 38.4 ± 4.3 | < 0.001 |
Values are expressed as mean±SD, median (IQR), or number (%).
*CKD was divided into HD and non-dialysis CKD; non-dialysis CKD was further classified as stage 3, 4, and 5, according to the KDIGO classification [11].
Abbreviations: CKD, chronic kidney disease; WBC, white blood cell; HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; Alb, albumin; IQR, Interquartile range; KDIGO, Kidney Disease Improving Global Outcomes.
Baseline and clinical characteristics according to the presence of bacteriuria in the patients with pyuria
| Sterile pyuria (N = 67) | UTI (N = 19) | ||
|---|---|---|---|
| Male sex, N (%) | 30 (44.8) | 2 (10.5) | 0.007 |
| Age (yr) | 68 (57–77) | 74 (64–78) | 0.164 |
| Presence of diabetes, N (%) | 44 (65.7) | 13 (68.4) | 1.000 |
| Stage of CKD*, N (%) | 0.049 | ||
| Stage 3 | 18 (26.9) | 5 (26.3) | |
| Stages 4 and 5 | 17 (25.4) | 10 (52.6) | |
| HD | 32 (47.8) | 4 (21.1) | |
| Blood | |||
| Hb (g/L) | 108.9 ± 16.0 | 107.7 ± 14.9 | 0.776 |
| WBC (× 109/L) | 6.8 ± 1.9 | 7.0 ± 1.6 | 0.618 |
| hs CRP (nmol/L) | 34.5 ± 54.9 | 35.9 ± 50.8 | 0.924 |
| Alb (g/L) | 38.1 ± 3.5 | 38.4 ± 5.0 | 0.825 |
| Urinary WBCs (/HPF), N (%) | 0.002 | ||
| 5–9 | 36 (53.7) | 2 (10.5) | |
| 10–19 | 11 (16.4) | 2 (10.5) | |
| 20–49 | 9 (13.4) | 7 (36.8) | |
| ≥ 50 | 11 (16.4) | 8 (42.1) | |
| Presence of urinary nitrites, N (%) | 3 (4.5) | 10 (52.6) | < 0.001 |
| Presence of proteinuria, N (%) | 46 (68.7) | 12 (63.2) | 0.782 |
| Presence of hematuria, N (%) | 25 (37.3) | 4 (21.1) | 0.273 |
| Urinary cell distribution | |||
| Neutrophils (%) | 70.2 ± 29.2 | 92.8 ± 10.1 | < 0.001 |
| Lymphocytes (%) | 18.8 ± 24.8 | 4.7 ± 9.1 | 0.001 |
| Monocytes (%) | 9.9 ± 12.0 | 2.1 ± 2.0 | < 0.001 |
Values are expressed as mean±SD, median (IQR), or number (%).
*CKD was divided into HD and non-dialysis CKD; non-dialysis CKD was further classified as stages 3, 4, and 5, according to the KDIGO classification [11].
Abbreviations: UTI, urinary tract infection; CKD, chronic kidney disease; WBC, white blood cell; hs CRP, high sensitivity C-reactive protein; Alb, albumin; HPF, high-power field; HD, hemodialysis; IQR, interquartile range; KDIGO, Kidney Disease Improving Global Outcomes.
Univariate and multivariate analyses for predicting UTI in patients with pyuria (N=86)
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR(95% CI) | OR(95% CI) | |||
| Age (yr) | 1.03 (0.99–1.08) | 0.176 | ||
| Sex (male) | 0.15 (0.03–0.68) | 0.014 | ||
| Presence of diabetes | 1.13 (0.38–3.37) | 0.823 | ||
| Stage of CKD* | 0.062 | |||
| Stage 3 | ||||
| Stages 4 and 5 | 2.12 (0.60–7.48) | 0.244 | ||
| HD | 0.45 (0.11–1.89) | 0.276 | ||
| HD (vs. non-dialysis) | 0.29 (0.09–0.97) | 0.045 | ||
| Degree of pyuria (/HPF) | 0.008 | |||
| 5–9 | 1 | 1 | ||
| 10–19 | 3.27 (0.41–26.01) | 0.262 | 12.34 (0.33–458.88) | 0.173 |
| 20–49 | 14.00 (2.48–79.20) | 0.003 | 31.23 (1.46–667.82) | 0.028 |
| ≥ 50 | 13.09 (2.41–70.96) | 0.003 | 38.32 (2.02–726.79) | 0.015 |
| Urinary cell distribution | ||||
| Neutrophils (%) | 1.07 (1.02–1.13) | 0.013 | 1.10 (1.01–1.20) | 0.039 |
| Lymphocytes (%) | 0.95 (0.90–1.00) | 0.055 | ||
| Monocytes (%) | 0.81 (0.68–0.97) | 0.025 | ||
| Presence of urinary nitrites | 23.33 (5.38–101.19) | < 0.001 | 45.41 (3.35–615.97) | 0.004 |
| Proteinuria | 0.78 (0.27–2.27) | 0.652 | ||
| Hematuria | 1.60 (0.47–5.41) | 0.453 | ||
| Plasma Hb (g/L) | 0.99 (0.96–1.03) | 0.773 | ||
| Plasma WBC (× 109/L) | 1.07 (0.83–1.38) | 0.615 | ||
| Serum hs CRP (nmol/L) | 1.00 (0.99–1.01) | 0.923 | ||
| Serum Alb (g/L) | 1.02 (0.89–1.16) | 0.822 | ||
*CKD was divided into HD and non-dialysis CKD; non-dialysis CKD was further classified as stage 3, 4, and 5, according to the KDIGO classification [11].
Abbreviations: UTI, urinary tract infection; CKD, chronic kidney disease; HPF, high-power field; WBC, white blood cell; hs CRP, high sensitivity C-reactive protein; Alb, albumin; HD, hemodialysis; OR, odds ratio; CI, confidence interval; KDIGO, Kidney Disease Improving Global Outcomes.
Fig. 2ROC curves showing the effectiveness of the number and distribution of urinary WBCs in UTI identification. The number of WBCs was analyzed at different cut-off values: ≥10, ≥20, and ≥50 WBCs/HPF.
Abbreviations: ROC, receiver operating characteristic; UTI, urinary tract infection; WBC, white blood cells; HPF, high-power field.